Log in

NYSE:TAKTakeda Pharmaceutical Stock Price, Forecast & News

$17.48
-0.01 (-0.06 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.37
Now: $17.48
$17.53
50-Day Range
$17.48
MA: $18.61
$19.50
52-Week Range
$12.43
Now: $17.48
$20.92
Volume661,300 shs
Average Volume1.17 million shs
Market Capitalization$55.11 billion
P/E Ratio124.87
Dividend Yield3.50%
Beta1
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has a collaboration agreement with Lupus Therapeutics Inc. to evaluate the investigational biologic TAK-079 as a potential new therapy for Lupus in a Phase 1 trial. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.1Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone813-3278-2111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.20 billion
Cash Flow$3.45 per share
Book Value$13.80 per share

Profitability

Net Income$407.02 million

Miscellaneous

Employees47,495
Outstanding Shares3,152,750,000
Market Cap$55.11 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.

Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

How has Takeda Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TAK shares have increased by 1.9% and is now trading at $17.48. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Takeda Pharmaceutical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Takeda Pharmaceutical.

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Takeda Pharmaceutical.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Co Ltd (NYSE:TAK) issued its earnings results on Wednesday, May, 13th. The company reported $0.13 earnings per share for the quarter. The firm earned $7.09 billion during the quarter. Takeda Pharmaceutical had a net margin of 1.37% and a return on equity of 13.80%. View Takeda Pharmaceutical's earnings history.

What price target have analysts set for TAK?

4 analysts have issued 12-month price targets for Takeda Pharmaceutical's stock. Their forecasts range from $19.50 to $30.00. On average, they expect Takeda Pharmaceutical's share price to reach $24.75 in the next year. This suggests a possible upside of 41.6% from the stock's current price. View analysts' price targets for Takeda Pharmaceutical.

Has Takeda Pharmaceutical been receiving favorable news coverage?

News articles about TAK stock have been trending negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Takeda Pharmaceutical earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Takeda Pharmaceutical.

Who are some of Takeda Pharmaceutical's key competitors?

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Alibaba Group (BABA), Verizon Communications (VZ), Johnson & Johnson (JNJ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T), Abbott Laboratories (ABT) and Walt Disney (DIS).

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the following people:
  • Mr. Christophe Weber, Pres, CEO & Representative Director (Age 53)
  • Dr. Andrew S. Plump, Chief Medical & Scientific Officer and Director (Age 54)
  • Dr. Seigo Izumo M.D., Chair of Management Board
  • Mr. Costa Saroukos, Chief Financial Officer (Age 48)
  • Mr. Haruhiko Hirate, Member of Management Board & Corp. Communications and Public Affairs Officer (Age 62)

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.01%) and Ellevest Inc. (0.00%).

Which institutional investors are buying Takeda Pharmaceutical stock?

TAK stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., and Ellevest Inc..

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $17.48.

How big of a company is Takeda Pharmaceutical?

Takeda Pharmaceutical has a market capitalization of $55.11 billion and generates $30.20 billion in revenue each year. The company earns $407.02 million in net income (profit) each year or $1.78 on an earnings per share basis. Takeda Pharmaceutical employs 47,495 workers across the globe.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is www.takeda.com.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company can be reached via phone at 813-3278-2111.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.